Clinical Trial Update: Bioequivalence Study for Acarbose / Metformin FDC [Phase 1]

View source ↗

Summary

A Phase 1 bioequivalence study evaluating a fixed-dose combination of acarbose and metformin for type 2 diabetes has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Acarbose/metformin fixed-dose combination (acarbose and metformin)

Snippet

Sponsor: Bayer | Conditions: Diabetes Mellitus, Type II | Phase 1 | Status: COMPLETED